Article Text

PDF
Autoantibodies to cyclic citrullinated peptide in a PMR inception cohort from The PMR Outcomes Study
  1. B Dasgupta1,
  2. A Hutchings2,
  3. J Hollywood3,
  4. L Nutter3
  1. 1
    Health and Human Sciences, Essex University, Southend University Hospital NHS Foundation Trust, UK
  2. 2
    Health Services Research Unit, London School of Hygiene and Tropical Medicine, UK
  3. 3
    Southend University Hospital NHS Foundation Trust; UK
  1. Dr B Dasgupta, Department of Rheumatology, Southend Hospital NHS Trust, Prittlewell Chase, Westcliff-on-sea, SS0 8PH, UK; bhaskar.dasgupta{at}southend.nhs.uk

Statistics from Altmetric.com

The lack of a laboratory test causes difficulties in distinguishing true polymyalgia rheumatica (PMR) from other inflammatory rheumatic diseases.1 An important differential diagnosis is rheumatoid arthritis (RA), which has been reported to develop in up to a third of patients.2

Antibodies to cyclic citrullinated peptides (CCP) are considered to have 96% specificity for RA.3 A study comparing 57 patients with elderly onset RA with 49 patients with PMR found that 65% in the first group were anti-CCP positive, whereas none of the patients with PMR were positive.4

We have reported on a continuing prospective inception PMR cohort study of clinical outcomes, quality of life and diagnostic uncertainty of patients recruited before the start of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.